Trial reportDiabetes, obesity & metabolism2019
First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes.
Trial report in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes.Diabetes, obesity & metabolism · 2019Trial
- Advancing the Development of Subcutaneous Glucose Biosensors: Cargo-Carrying Adhesive Biosensor Systems (CABs).Macromolecular bioscience · 2026Article
- Towards Standardization of CGM Performance Studies: The QUSS-CGM Questionnaire for Assessing User Satisfaction.Patient related outcome measures · 2025Article
- Continuous Glucose Monitoring-New Diagnostic Tool in Complex Pathophysiological Disorder of Glucose Metabolism in Children and Adolescents with Obesity.Diagnostics (Basel, Switzerland) · 2024Review
- Evidence from clinical trials on high-risk medical devices in children: a scoping review.Pediatric research · 2024Article
- Evaluating the precision and reliability of real-time continuous glucose monitoring systems in ambulatory settings: a systematic review.Therapeutic advances in endocrinology and metabolism · 2024Review
- Clinical Performance Evaluation of Continuous Glucose Monitoring Systems: A Scoping Review and Recommendations for Reporting.Journal of diabetes science and technology · 2023Article
- Miniaturization of an Osmotic Pressure-Based Glucose Sensor for Continuous Intraperitoneal and Subcutaneous Glucose Monitoring by Means of Nanotechnology.Sensors (Basel, Switzerland) · 2023Article
- Article
- Catalytic Biosensors Operating under Quasi-Equilibrium Conditions for Mitigating the Changes in Substrate Diffusion.Angewandte Chemie (International ed. in English) · 2022Article
- Technologies for Diabetes Self-Monitoring: A Scoping Review and Assessment Using the REASSURED Criteria.Journal of diabetes science and technology · 2022Article
- Clinical Use of a 180-Day Implantable Glucose Monitoring System in Dogs with Diabetes Mellitus: A Case Series.Animals : an open access journal from MDPI · 2022Article
- Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study.Diabetes technology & therapeutics · 2022Article
- Advancing continuous subcutaneous insulin infusion in vivo: New insights into tissue challenges.Journal of biomedical materials research. Part A · 2021Article
- Continuous Glucose Monitoring Devices: Past, Present, and Future Focus on the History and Evolution of Technological Innovation.Journal of diabetes science and technology · 2021Review
- Coexistence of medium chain acyl-CoA dehydrogenase deficiency (MCADD) and type 1 diabetes (T1D): a management challenge.BMJ case reports · 2021Article
- Review of the Long-Term Implantable Senseonics Continuous Glucose Monitoring System and Other Continuous Glucose Monitoring Systems.Journal of diabetes science and technology · 2021Article
- A Review of the First Long-term Implantable Continuous Glucose Monitoring System Available in the United States.Journal of diabetes science and technology · 2021Review
- Noninvasive, wearable, and tunable electromagnetic multisensing system for continuous glucose monitoring, mimicking vasculature anatomy.Science advances · 2020Article
- 12th Roche Diabetes Care Network Meeting: April 11-13, 2019, Copenhagen, Denmark.Diabetes technology & therapeutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the performance of the Eversense XL implantable continuous glucose monitoring (CGM) system through 180 days in a primarily adolescent population with type 1 diabetes (T1D). MATERIALS AND
methodsThis prospective, single-centre, single-arm, 180-day study evaluated the effectiveness and safety of the implantable CGM system in Canadian adolescent and adult subjects with T1D. Accuracy measures included mean absolute relative difference (MARD), 15/15% agreement between CGM glucose and blood glucose measured by Yellow Springs Instruments and surveillance error grid analysis. Adolescent subjects received one sensor in the upper arm and adult subjects received one sensor in each upper arm. In-clinic CGM system accuracy studies were performed every 30 days. The safety assessment included the incidence of adverse events related to either device or the insertion/removal procedure through 180 days.
resultsThirty-six subjects (30 adolescent/6 adult, 13 female/23 male, mean age 17 ± 9.2 years, mean body mass index 22 ± 4 kg/m
conclusionThe Eversense XL CGM system is safe and accurate through 180 days in a primarily adolescent population of subjects with T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.